Medtronic Trial for AFib System Achieves Endpoints
By Ben Glickman
Medtronic said its combined system for use during treatment of atrial fibrillation reached its safety and efficacy endpoints in a trial.
The medical-device company said that the Affera Mapping and Ablation System with Sphere-9 Catheter, an ablation and mapping system, showed higher freedom from AFib compared with the control arm of the trial and had a comparable safety profile.
The Affera system with Sphere-9 catheter was specifically being evaluated in cases of persistent AFib, which makes up 30% to 50% of patients.
The company said it had recently filed for approval of the combined system in the U.S.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
May 17, 2024 17:03 ET (21:03 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations